Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens

Sean Kirby1, Anjali Satoskar1, Sergey Brodsky1, Amy Pope-Harman2, David Nunley2, Charles Hitchcock1, Ronald Pelletier3, Patrick Ross3, Tibor Nadasdy1 and Konstantin Shilo1*

Abstract

Background: After the introduction of novel effective immunosuppressive therapies, kidney transplantation became the treatment of choice for end stage renal disease. While these new therapies lead to better graft survival, they can also cause a variety of complications. Only small series or case reports describe pulmonary pathology in renal allograft recipients on mTOR inhibitor inclusive therapies. The goal of this study was to provide a systematic review of thoracic biopsies in kidney transplant recipients for possible association between a type of immunosuppressive regimen and pulmonary complications.

Methods: A laboratory database search revealed 28 of 2140 renal allograft recipients (18 males and 10 females, 25 to 77 years old, mean age 53 years) who required a biopsy for respiratory symptoms. The histological features were correlated with clinical findings including immunosuppressive medications.

Results: The incidence of neoplasia on lung biopsy was 0.4% (9 cases), which included 3 squamous cell carcinomas, 2 adenocarcinomas, 1 diffuse large B-cell lymphoma, 1 lymphomatoid granulomatosis, and 2 post transplant B-cell lymphoproliferative disorders. Diffuse parenchymal lung disease was identified in 0.4% (9 cases), and included 5 cases of pulmonary hemorrhage, 3 cases of organizing pneumonia and 1 case of pulmonary alveolar proteinosis. Five (0.2%) cases showed histological features indicative of a localized infectious process. Patients on sirolimus had neoplasia less frequently than patients on other immunosuppressive combinations (12.5% vs. 58.3%, p = 0.03). Lung biopsies in 4 of 5 patients with clinically suspected sirolimus toxicity revealed pulmonary hemorrhage as the sole histological finding or in combination with other patterns.

Conclusions: Our study documents a spectrum of neoplastic and non-neoplastic lesions in renal allograft recipients on current immunosuppressive therapies. Sirolimus inclusive regimens are associated with increased risk of pulmonary toxicity but may be beneficial in cases of posttransplant neoplasia.

Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3320012126569395.

Keywords: Kidney transplantation, Pulmonary neoplasia, Pulmonary hemorrhage, Mammalian target of rapamycin (mTOR) inhibitors, Sirolimus
Background

Kidney transplantation is considered the treatment of choice for end stage renal disease (ESRD), which is in part due to availability of more effective immunosuppressive regimens. The mammalian target of rapamycin (mTOR) inhibitors, rapamycin, also known as sirolimus, and everolimus, have been recently widely utilized in immunosuppressive regimens providing adequate immunosuppression and avoiding nephrotoxic side effects of calcineurin inhibitor therapy [1-4]. However, prolonged graft survival leads to increased incidence of complications related to both immunosuppression and drug toxicity. Drug induced immunosuppression halts tumor surveillance leading to an increase in tumor development. Epidemiologic studies show that posttransplant lymphoproliferative disorder (PTLD) and skin cancers increased most dramatically following kidney transplantation [5-8]. In addition to immunosuppression, sirolimus exhibits antineoplastic properties in vivo [9] and newer rapamycin analogs have been evaluated in clinical trials for treatment of renal cell carcinoma [10]. Clinical experience with these medications is limited; but it has been shown to cause regression of PTLD and Kaposi sarcoma [11-14]. The incidence of pulmonary toxicity in patients on mTOR inhibitors has been reported to be up to 11% [15,16]. Risk factors for the development of sirolimus-associated pneumonitis include higher dose, greater trough levels and older age [17]. While the contribution of other causes in the setting of mTOR inhibitor induced immunosuppression is difficult to separate from direct drug toxicity, a range of pulmonary histopathologic changes has been suggested as manifestations of drug toxicity. Depending on biopsy modality these include descriptive diagnoses or better-defined histological patterns such as organizing pneumonia and diffuse alveolar hemorrhage [15,16,18-20]. Pulmonary hemorrhage has been reported as a sole histological finding [21] but also in combination with others [18]. Other rare pulmonary manifestations include pulmonary alveolar proteinosis [22], desquamative interstitial pneumonitis [23], hypersensitivity pneumonitis [24], necrotizing granulomas and vasculitis [25], diffuse alveolar damage [26] and non-necrotizing granulomas [19]. Since the reported histological manifestations are not specific for sirolimus toxicity, drug discontinuation with or without steroid therapy is the mainstay of treatment in suspected cases and typically leads to resolution of symptoms within 2 to 4 months [18]. To the best of our knowledge, only small series or case reports describe pulmonary pathology in renal allograft recipients and the concept of sirolimus-associated pulmonary complications is still evolving. Therefore, the goals of this study were to provide a systematic review of pulmonary histological findings in the setting of kidney transplantation and elucidate the possible contribution of the current immunosuppressive regimens to the spectrum of the observed histological changes.

Material and methods

A laboratory information system database search from January 2002 to September 2010 revealed 28 renal allograft recipients who required a lung biopsy for respiratory symptoms. In total, 42 biopsies were performed, including 8 (19%) video-assisted thoracoscopic biopsies, 28 (67%) endobronchial biopsies, 5 (12%) needle biopsies, and 1 (2%) mediastinal lymph node biopsy. Sixteen (38%) biopsies were nondiagnostic. Biopsies were considered nondiagnostic if they had limited tissue or minimal nonspecific histological changes such as chronic inflammation or focal interstitial fibrosis. Hematoxylin-eosin (H&E) stained slides (range, 1-19; mean, 3 slides) and special stains for microorganisms including Gomori methenamine silver, Ziehl-Neelsen and gram stains, performed on formalin-fixed, paraffinembedded tissue were re-examined. The radiology studies including chest computed tomography (CT) were reviewed in respect to localized versus diffuse changes. Localized lesions included nodules or masses while the diffuse lesions were comprised of diffuse or patchy bilateral ground glass opacities, reticular densities, bilateral consolidations, mosaic attenuation, and traction bronchiectasis. Retrospective analysis of electronic clinical records and correlation with histological findings and type of immunosuppressive therapy were performed. The electronic medical records were reviewed with special attention for evidence of systemic diseases and infectious complications including microbiological cultures and serologies for viral and fungal pathogens. Review of immunosuppressive regimens included an active list of medications pre-and post-lung biopsy. Clinical and pathological findings were analyzed utilizing mean ± SD for continuous variables, and number or percentage for categorical variables. Comparisons were performed using Yates’ chi-square test for categorical variables, and the two-sample t test for continuous variables. The study was approved by The Ohio State Biomedical Sciences Institutional Review Board in compliance with Health Insurance Portability and Accountability Act regulations.

Results

Clinicopathological findings in patients with kidney transplant

The main clinical and pathological findings are summarized in Table 1. Twenty-eight of 2140 (1.3%) kidney transplant recipients over the period of 105 months underwent a lung biopsy for pulmonary symptoms. They included 18 males and 10 females with an age
## Table 1 Clinical pathological findings in kidney transplant recipients

| Age, years | Gender | Kidney disease | Transplant type | Time, mos | Sirolimus trough levels, mean (range), ng/ml | Other immuno-suppressants | Clinical radiological presentation | Biopsy type | Pathological findings |
|------------|--------|----------------|----------------|----------|---------------------------------------------|---------------------------|----------------------------------|-------------|----------------------|
| 1* 49      | M**    | DM1            | K/Cad          | 11       | 11.7(6.2-18.7)                             | C/P                       | Bilateral mass-like consolidations | EB          | ND                   |
| 2          | 25     | F              | DM1            | K/Cad    | 20                                           | C/MY/D                    | Patchy bilateral consolidations  | EB          | BCLPD                |
| 3          | 71     | M              | PCKD           | K/Cad    | 36                                           | C/D                       | Mediastinal lymphadenopathy      | EB          | LNB                 | DLBCL         |
| 4          | 58     | F              | DM2            | K/Cad    | 5                                            | 8.8(4.0-17.1)             | Respiratory failure Diffuse ground glass opacities | EB          | THB                 | Hemorrhage    |
| 5          | 47     | F              | HTN            | K/Cad    | 210                                          | C/MY/P                    | Respiratory failure, loculated pneumonia | EB          | Necrosis            | Fibrin        |
| 6          | 72     | M              | DM2            | K/Cad    | 20                                           | 4.8(2.0-8.2)             | Spiculated lung lesion           | NB          | SQC                 |
| 7          | 77     | M              | K/Cad          |          | 116                                          | C/D                       | Pulmonary nodule                 | EB          | SQC                 |
| 8          | 71     | M              | pANCA          | K/Cad    | 10                                           | 15.1                      | Right lower lobe mass            | EB          | ND                  |
| 9          | 48     | F              | NA             | K/Cad    | 32                                           | NA                        | Left lower lobe nodule           | EB          | Necrosis            | Fibrin        |
| 10         | 39     | M              | GN             | K/Cad    | 80                                           | 10.2(8.1-11.8)           | Respiratory failure, diffuse ground glass opacities with crazy paving pattern | THB         | Hemorrhage           | PAP           | OP                  |
| 11         | 45     | F              | NA             | K/Cad, LR| 345                                          | C/P                       | Collapsed lung pneumonia         | EB          | OP                  |
| 12         | 58     | F              | HTN            | K/Cad    | 24                                           | 19.7                      | Respiratory failure, diffuse ground glass opacities | EB          | THB                 | Hemorrhage    |
| 13         | 44     | F              | DM2            | K/LR     | 36                                           | 5.3(3.2-6.9)             | Mediastinal lymphadenopathy, patchy ground glass opacities | EB          | ND                  |
| 14         | 46     | M              | WG             | K/LR     | 175                                          | C/MY/P                    | Diffuse ground glass opacities, lung nodules | EB          | Hemorrhage           | Capillaritis   |
| 15         | 49     | F              | DM             | K        | 73                                           | 8.1(4.3-11.6)            | Bilateral ground glass opacification with right lower lobe consolidation | EB          | OP                  |
| 16         | 34     | F              | DM1            | KP/Cad   | 19                                           | 4.2(2.4-6.7)             | Respiratory failure, diffuse ground glass opacities | THB         | DAD                 | Hemorrhage    |
| 17         | 43     | M              | DM1            | KP       | 41                                           | 4.4                       | Nodular right lower lobe infiltrate | EB          | ND                  |
| 18         | 69     | M              | DM2            | K/LU     | 4                                            | 11.0(5.0-14.9)           | Bilateral lung nodules and mediastinal lymphadenopathy | EB          | BCLPD               |
| 19         | 71     | M              | IgA            | K/LR     | 114                                          | C/P                       | Dyspnea, diffuse ground glass opacities | EB          | PAP                 |
| 20         | 60     | M              | GN             | K/LR     | 89                                           | C/MY/D                    | Lung nodule                      | EB          | ND                  |
| 21         | 65     | M              | K/LR           |          | 41                                           | 6.8(2.8-12.0)            | Bilateral hypermetabolic lung nodules | THB         | PJ                  | granulomas     |
| 22         | 60     | M              | GN             | K/LR     | 66                                           | C/P                       | Lung mass                        | THB         | ADC                 |
| 23         | 52     | M              | DM1            | KP/Cad   | 73                                           | C/P                       | Lung mass                        | EB          | SQC                 |
| 24         | 34     | M              | GN             | K/Cad    | 38                                           | 10.2(6.1-14.3)           | Bilateral ground glass opacities Loculated right sided pleural effusion | EB          | Fibrin              | Necrosis      |
| 25         | 36     | F              | NA             | K        | 180                                          | C/P                       | Bilateral lung nodules, lymphadenopathy | THB         | NB                  | LYG           |
| 26         | 62     | M              | IN             | K/LR     | 115                                          | C/P                       | Lung mass                        | NB          | ADC                 |
| 27         | 53     | M              | PCKD           | K/LU     | 61                                           | 2.0                       | Lung nodule, pleural effusion    | EB          | ND                  |
| 28         | 32     | M              | CR             | K/LU     | 220                                          | 8.6(4.4-13.2)            | Dyspnea, patchy ground glass opacities | EB          | OP                  |

(*) - the cases are arranged in chronological order; (**) - M male; F female; DM diabetes mellitus; PCKD polycystic kidney disease; HTN hypertension; p-ANCA p-ANCA vasculitis; GN glomerulonephritis; WG Wegner’s granulomatosis; IgA IgA nephropathy; IN interstitial nephritis; CR chronic reflux; K kidney transplant; KP kidney and pancreas transplant; Cad cadaveric kidney; LR living related kidney; LU living unrelated kidney; EB endobronchial biopsy; THB thoracoscopic biopsy; NB needle biopsy; LNB lymph node biopsy; C cyclosporine; P prednisone; D dexamethasone; MY mycophenolate mofetil; MA mycophenolic acid; ND not diagnostic; SQC squamous cell carcinoma; ADC adenocarcinoma; BCLPD B-cell lymphoproliferative disorder; DLBCL diffuse large B-cell lymphoma; LYG lymphomatoid granulomatosis; OP organizing pneumonia; DAD diffuse alveolar damage; PJ Pneumocystis jiroveci; PAP pulmonary alveolar proteinosis; NA not available
range from 25 to 77 years old (mean age of 53 years).
The time from kidney transplantation to lung biopsy ranged from 4 to 345 months (mean 81 months). In 19 cases (68%) the biopsies were performed to obtain tissue diagnosis for localized lesions, and in 9 cases (32%) for diffuse lesions. The majority of patients (18/28 or 64%) received a deceased donor kidney. Eight patients (29%) received kidneys from living related donors; two patients (7%) received kidneys from living unrelated donors. One patient received three transplants, including two cadaveric and one living related. Twenty-five (89%) patients had kidney-only transplant, while three patients (11%) had a combined kidney and pancreas transplantation. The most common cause of ESRD was diabetic nephropathy (10/28; 36%). Other causes included hypertension (2/28; 7%), polycystic kidney disease (2/28; 7%), glomerulonephritis (4/28; 14%), granulomatosis with polyangiitis (Wegner’s granulomatosis) (1/28; 4%), IgA nephropathy (1/28; 4%), chronic reflux (1/28; 4%), p-ANCA-positive microscopic polyangiitis (1/28; 4%), and interstitial nephritis (1/28; 4%).

Neoplasia on lung biopsy was identified in 9 (0.4%) of 2140 kidney transplant recipients. Among 9 cases there were 5 non-small cell carcinomas and 4 PTLD. Non-small cell carcinomas included 3 cases of squamous cell carcinoma and 2 cases of adenocarcinoma (Figure 1A). PTLD included 1 case of diffuse large B-cell lymphoma, 1 case of lymphomatoid granulomatosis (Figure 1B-C) and 2 cases of post transplant B-cell lymphoproliferative disorders. Diffuse parenchymal lung disease was identified in 9 (0.4%) cases. In 2 cases, pulmonary hemorrhage (PH) was the sole histological finding. In 1 case PH was associated with capillaritis. In 1 case PH was associated with pulmonary alveolar proteinosis (PAP) and in 1 case with diffuse alveolar damage (DAD). PH associated with capillaritis was documented in a patient with WG and was considered a pulmonary manifestation of the disease. Organizing pneumonia (OP) as the main histological finding was identified in 3 cases and PAP was identified in 1 case. Five (0.2%) cases showed histological features indicative of an infectious process including tissue necrosis, necrotic cellular debris, acute inflammation, and granulomas. In 1 of 5 cases, granulomatous inflammation was associated with *Pneumocystis jiroveci* (Figure 1D). Lung biopsy showed minimal findings in 5 (0.2%) patients.

**Clinicopathological findings in patients on sirolimus**

All patients with a lung tissue diagnosis received combination immunosuppressive therapy. The immunosuppressive regimen of 16 of 28 (57%) patients included...
sirolimus. Other immunosuppressants were comprised of cyclosporine (25/28; 89%), prednisone (23/28; 82%), dexamethasone (4/28; 14%), mycophenolate mofetil (6/28; 21%), and mycophenolic acid (2/28; 7%). The groups of patients receiving sirolimus versus other immunosuppressive medications were of similar age and gender (Table 2). However, the mean time from the transplant to lung biopsy of patients on sirolimus was shorter (44.7 ± 52.04 vs. 128.3 ± 89.32, *p* = 0.01). Patients on sirolimus less frequently than patients on other immunosuppressants had neoplasia (12.5% vs. 58.3%, *p* = 0.03). Tumors in patients on sirolimus included 1 squamous cell carcinoma and 1 post transplant B-cell lymphoproliferative disorder. Tumors in the non-sirolimus group included 2 adenocarcinomas, 2 squamous cell carcinomas, 1 posttransplant B-cell lymphoproliferative disorders, 1 diffuse large B-cell lymphoma and 1 lymphomatoid granulomatosis. Patients on sirolimus had a tendency to have diffuse parenchymal lung disease (37.5% vs. 25.0%), including hemorrhage (25.0% vs. 8.3%). The results, although suggestive of an association, did not achieve statistical significance.

### Sirolimus toxicity and response to treatment modification
Sirolimus toxicity was suspected clinically in 5 (31.3%) of 16 patients. Their mean trough sirolimus levels were not statistically different from the other 10 cases on sirolimus (10.3 ± 5.72 ng/ml vs. 7.6 ± 3.56 ng/ml). Among these 5 cases, lung biopsies in 4 revealed pulmonary hemorrhage and OP, in 1. All 5 patients showed clinical and radiological improvement after the drug discontinuation. Their clinical course and response to treatment modification is detailed below.

In case 4, a 54 year old woman was admitted with recurrent shortness of breath for the fourth time in the five months following kidney transplant. The patient had a past medical history of chronic obstructive pulmonary disease and congestive heart failure with basic oxygen requirements of 3-4 l via nasal cannula. On her current admission she was in severe respiratory failure, requiring mechanical ventilation. Her trough sirolimus levels following transplantation were within range from 4.0 to 17.1, (mean, 8.8), normal 3-20 ng/ml. A chest CT on admission showed diffuse ground glass opacities and pleural effusions. Endobronchial biopsy was nondiagnostic, while a subsequent open lung biopsy showed collections of hemosiderin laden macrophages occupying alveolar spaces as well as hemosiderin granules within interstitium (Figure 2A). Evaluation for infectious organisms and vasculitis was negative. Since treatment for infection did not produce any significant improvement, sirolimus toxicity was suspected and sirolimus was discontinued. The patient returned to baseline respiratory status (3-4 l of oxygen) with improvements in bilateral opacities radiologically within 6 months. Following discharge, the patient required a single readmission for respiratory symptoms over the subsequent 33 months. At that time she was admitted for respiratory failure and subsequently expired. Postmortem examination revealed extensive hemosiderin deposition and a left upper lobe adenocarcinoma.

Case 10 is that of a 39-year-old African-American male, 80 months post kidney transplantation,
Figure 2 Pathological findings in patients with sirolimus toxicity. In case 4, open lung biopsy shows diffuse alveolar hemorrhage represented by collections of hemosiderin laden alveolar macrophages (A, inset) and occasional hemosiderin granules within interstitium, (hematoxylin-eosin, original magnification x100 and x400, respectively). In case 10, open lung biopsy shows pulmonary hemorrhage in association with pulmonary alveolar proteinosis and organizing pneumonia: there are areas with hemosiderin deposition within interstitium (B) and cholesterol granulomas, finely granular proteinaceous material with cholesterol clefting (C) and foci of organizing pneumonia (D) in adjacent alveolar parenchyma, (hematoxylin-eosin, original magnification x100, x200 and x 40, respectively). Computed tomography of the chest at the time of open lung biopsy shows diffuse ground glass and “crazy pavement” opacities (E). Follow up computed tomography in 8 months (F) shows marked decrease in alveolar opacities; both scans are at the level of aortic arch for comparison. In case 16, open lung biopsy shows a combination of diffuse alveolar damage and pulmonary hemorrhage; there are edematous alveolar septae lined by hyaline membranes (G) and hemosiderin-laden macrophages (H) within alveolar spaces (H&E, original magnification x200 and x400, respectively).
hospitalized for increasing shortness of breath with increasing creatinine levels. His progressive hypoxia resulted in intubation. A chest CT showed diffuse bilateral ground glass opacities, “crazy pavement” pattern and focal nodular consolidation. His trough sirolimus levels within 6 months prior to admission were 8.1-11.8, (mean, 10.2) normal, 3-20 ng/ml. Hemosiderin laden macrophages associated with rare cholesterol granulomas were seen on transbronchial biopsy. His respiratory status continued to deteriorate and open lung biopsy was performed that showed alveolar and interstitial hemosiderin deposition accompanied by patchy organizing pneumonia, cholesterol granulomas and eosinophilic proteinaceous granular material (Figure 2B-D). The findings were compatible with a combination of PH and PAP. He underwent therapeutic bronchioloalveolar lavage and the decision was made to discontinue all immunosuppressive medications other than prednisone. During his nearly 2 month hospital stay, he was gradually weaned from ventilation support and his oxygen requirement at the time of discharge was 2 l of oxygen. Over the ensuing 8 months he showed clinical and radiological improvement (Figure 2E-F) on mycophenolate maintenance therapy. At 3.5 years of follow up, the patient was on maintenance mycophenolate therapy, and his symptoms were found, sirolimus toxicity was suspected. Sirolimus was discontinued and he was given a course of oral corticosteroids. Over the following 2 months, his respiratory status improved significantly, with no reported shortness of breath, cough or wheezing and discontinuation of supplemental oxygen.

Case 12 represents a 58-year old female who was hospitalized 24 months post kidney transplantation with shortness of breath, hypoxia, and renal failure. Her trough sirolimus level before admission was elevated to 19.7 ng/ml, normal 3-15 ng/ml. A bronchoscopic biopsy revealed occasional hemosiderin granules. Her symptoms did not improve and an open lung biopsy revealed histological evidence of PH with alveolar and interstitial hemosiderin deposition. Respiratory and blood cultures remained negative throughout the patient’s stay. Sirolimus was stopped and over the following 4 months she showed significant clinical improvement despite continued baseline oxygen requirements.

Case 16 is that of a 34-year old female who was hospitalized 17 months post kidney-pancreas transplant with two episodes of acute rejection. Her trough sirolimus levels were within range 2.4-6.7 ng/ml, mean 4.2 ng/ml, normal 3-15 ng/ml. Hemosiderin laden macrophages were present in the bronchioloalveolar lavage fluid. Sirolimus toxicity was suspected and sirolimus was discontinued. Despite extensive workup for infectious and rheumatologic etiologies and treatment with wide spectrum antibiotics she remained in respiratory failure. An open lung biopsy showed a combination of DAD and PH with hyaline membranes, architectural simplification with alveolar septal collapse, diffuse myxoid thickening, type 2 pneumocyte hyperplasia, and alveolar and interstitial hemosiderin (Figure 2G-H). The patient’s treatment also included mechanical ventilation, volume and blood pressure control. After 2 months at a rehabilitation facility, her shortness of breath and cough were significantly improved and chest CT revealed resolution of the bilateral infiltrates. On further follow-up, the patient reported minimal respiratory symptoms.

Case 28 represents a 31-year old male, 220 months post kidney transplantation, started to experience cough and dyspnea. He received a course of antibiotics for community-acquired pneumonia with no improvement. His trough sirolimus levels within previous 6 months were 4.4-13.2 ng/ml, (mean 8.6 ng/ml), normal 5-30 ng/ml. He underwent an extensive evaluation including a CT scan of the chest revealing extensive ground glass densities in a multifocal distribution. Evaluation for collagen vascular disease and infectious etiologies were negative, including a bronchoscopic examination with microbiological cultures. Transbronchial lung biopsy showed patchy organizing pneumonia and chronic inflammation. Since no systemic or infectious causes for his symptoms were found, sirolimus toxicity was suspected. Sirolimus was discontinued and he was given a course of oral corticosteroids. Over the following 2 months, his respiratory status improved significantly, with no reported shortness of breath, cough or wheezing and discontinuation of supplemental oxygen.

Discussion

Kidney transplant recipients are known to be at increased risk for malignancy with up to 2 fold increased incidence rates for lung cancer and 20-fold increased incidence rates of PTLD [5]. Our retrospective review shows a wide spectrum of neoplastic and non-neoplastic lesions in the lungs of kidney transplant recipients on current immunosuppressive regimens. Among the neoplastic lesions there were 5 cases of non-small cell lung carcinoma and 4 cases of PTLD with incidence of approximately 0.2% each. The incidence of lung carcinoma in our series was similar to what was previously reported in other single center cohorts [27,28], exceeding the incidence seen in general population [5]. The incidence of PTLD was lower, which is likely due to the fact that our study examined only lung biopsies and therefore couldn’t account for the PTLD involving other sites. PTLD reportedly affects 1.8% of patients with up to 50% of cases presenting with extranodal masses, including lung nodules [29-31].

When correlated to the type of immunosuppression, the frequency of neoplasia in patents on sirolimus was lower (12.5% vs. 58.3%, p = 0.03) relative to patients on
other immunosuppressants. It is possible that the longer transplant to lung biopsy time in the non-sirolimus group may have contributed to increased tumor detection. Nevertheless, our findings are in agreement with studies supporting antineoplastic properties of mTOR inhibitors in pre-clinical testing [9,32,33] and clinical studies of patients with post transplant solid organ tumors [28,34-36], suggesting that sirolimus may be beneficial in preventing posttransplant malignancies.

Our study also demonstrates that pulmonary hemorrhage is a common histological finding in cases with clinically suspected sirolimus toxicity. In this cohort, it can be seen as the sole histological finding or in combination with other histological patterns including DAD and PAP. Based on their own experience and review of the literature, Pham and colleagues list pulmonary hemorrhage, organizing pneumonia, and lymphocytic pneumonitis among the most common histological patterns of sirolimus toxicity [18]. From a clinical management point of view, the histological diagnosis of pulmonary hemorrhage carries a task of elucidating its possible causes which generally include alveolar hemorrhage syndromes or secondary causes associated with infections, toxic inhalation, coagulopathies, renal failure with volume overload, and venous congestion due to heart disease to name a few [37]. In our series only one case with PH was linked to Wegener’s granulomatosis. During their clinical course, the study patients experienced renal failure with wide fluctuation of serum creatinine levels; however, the renal function was generally well controlled, and none had clinically documented sustained fluid overload. In our cases pulmonary hemorrhage could not be explained by any other causes, and sirolimus discontinuation lead to the gradual clinical improvement. In case 4, the patient had congestive heart failure, which histologically can be associated with pulmonary hemosiderin deposition. Therefore, it is difficult to completely exclude the contribution of the patient’s underlying heart disease to the observed histological findings. In that regard, this case is similar to that reported by Hashemi-Sadraei N and colleagues [38]. They described a renal transplant recipient who was on chronic anticoagulation therapy for a prosthetic aortic valve, and who developed pulmonary symptoms following initiation of sirolimus therapy. An open lung biopsy showed diffuse alveolar hemorrhage with fibrin deposits in the alveolar spaces and small bronchi. Even though the underlying disease, congestive heart failure or heart valve requiring anticoagulation therapy, may have contributed to the pulmonary hemosiderin deposition, in both of these cases the response to sirolimus discontinuation suggests a causative association between the drug and pulmonary hemorrhage.

Other histological patterns identified within a spectrum of the diffuse parenchymal lung disease in patients on sirolimus were OP, DAD, and PAP. The spectrum of etiologic considerations in OP includes infection, collagen vascular disease, toxic inhalation, aspiration pneumonia, hypersensitivity pneumonitis, and drug toxicity [39,40]. Additionally, OP can be a minor component of other interstitial lung diseases. OP is one of the relatively frequently reported manifestations of sirolimus toxicity [18]. We identified OP as a main histological feature in 3 cases; however, it was also observed as a minor component in other cases including cases of pulmonary hemorrhage and DAD. This could be a reason for some discrepancy between reported frequencies of OP, especially if a diagnosis is rendered on a small endobronchial or transbronchial biopsy [18]. DAD is a well recognized histological pattern known to be associated with drug toxicity [41]. Among tissue reactions associated with sirolimus toxicity, only one case of DAD has been documented in the literature. Manito and colleagues [26] reported a fatal course of DAD in a 52-year-old man heart transplant recipient following a loading-dose of sirolimus administration. We observed DAD in one patient on sirolimus (case 16) where an open lung biopsy revealed a combination of DAD and pulmonary hemorrhage. No infectious or systemic disease was documented with extensive clinical evaluation. Despite wide spectrum antibiotics coverage, the patient showed a protracted clinical course but gradually improved over 2 months after sirolimus discontinuation showing only minimal pulmonary symptoms.

PAP is a rare poorly understood disorder that is characterized by accumulation of lipoproteinaceous surfactant-like material within alveolar parenchyma. Impaired macrophage function due to antibodies to granulocyte macrophage-colony stimulating factor is thought to be a key mechanism in primary PAP. Macrophage dysfunction due to immunosuppression is considered as one among many other causes of secondary PAP. It has been linked to sirolimus toxicity in 2 previously reported cases [22,42]. PAP histology in our series was documented in both sirolimus (1 case) and non-sirolimus (1 case) groups, suggesting that this is a secondary immunosuppression related tissue reaction that is not directly related to sirolimus toxicity.

Sirolimus induced immunosuppression results from the inhibition of T and B lymphocyte proliferation through the same mechanisms as it inhibits cancer cell proliferation. These effects are thought to be mediated through the rapamycin-FKB12 complex altering the mTOR signaling network which includes tumor suppressor genes (PTEN, LKB1, TSC1, and TSC2) and proto-oncogenes (PI3K, Akt, and eIF4E) [43]. While the exact mechanisms of sirolimus toxicity are not
known, several hypotheses have emerged. Clinical improvement after sirolimus dose reduction provides evidence for a dose-dependent pulmonary toxicity. Clinically and radiologically documented pneumonitis in kidney transplant recipients has been reported to improve dramatically after sirolimus dose reduction and the maintenance of lower trough levels [44]. BAL fluid analysis in cases of the drug induced alveolitis showed a predominance of CD4-positive lymphocytes allowing the authors to suggest that a cell mediated autoimmune response may be one of the factors responsible for sirolimus induced pulmonary toxicity [44]. Furthermore, it has been speculated that the drug’s high affinity for plasma proteins may render sirolimus immunogen as a hapten eliciting cascade of T-cell mediated delayed type of hypersensitivity reaction [18]. These hypotheses appear to capture the state of current knowledge; however, detailed mechanisms of sirolimus toxicity and their relationship to the spectrum of histological patterns of parenchymal lung disease are yet to be elucidated.

Conclusions

Our study documents that kidney transplant recipients show a range of pulmonary neoplastic and non-neoplastic lesions, which are likely associated with the type of immunosuppressive regimen. Current mTOR inhibitor inclusive regimens may account for decreased number of tumors in kidney transplant recipients but also carry a risk of pulmonary toxicity manifesting histologically by pulmonary hemorrhage, organizing pneumonia and other less common histological patterns.

Acknowledgements

The authors are thankful to Rick Marshall and Cheryl Reeder for help with database searches. The findings of the study were presented in part at the 100th United States and Canadian Academy of Pathology Annual Meeting, February 27 to March 4, 2011, San Antonio, Texas.

Author details

1 Department of Pathology, The Ohio State University Medical Center, Columbus, Ohio, USA. 2 Department of Medicine, The Ohio State University Medical Center, Columbus, Ohio, USA. 3 Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA.

Authors’ contributions

SK reviewed cases, analyzed findings and drafted the manuscript. AS, SB, AP-H, DN, RP, TN and KS designed the study, participated in data collection and edited the manuscript. CH and PR participated in data collection and edited the manuscript. KS also reviewed the cases, developed and approved the study protocol, revised and edited the manuscript. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 1 January 2012 Accepted: 14 March 2012 Published: 14 March 2012

References

1. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000, 356(9225):194-202.

2. Chapman JR, Valantine H, Albaranji J, Ames WA, Campistol JM, Eisen H, Frigerio M, Lehrkuhl H, Marcen R, Morris R, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007, 39(10):2937-2950.

3. Campistol JM, Albarran J, Ames W, Bolets I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Oyen O, Pascual J, et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. Nephrol Dial Transplant 2007, 22(Suppl 1):i6-41.

4. MacDonald AS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001, 71(2):271-280.

5. Kasiske BL, Snyder JJ, Valantine H, Ahmed D, Albaranji J, Ames WA, Campistol JM, Eisen H, Frigerio M, Lehrkuhl H, Marcen R, Morris R, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007, 39(10):2937-2950.

6. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M: Malignancy in renal transplantation. J Am Soc Nephrol 2004, 15(6):1582-1588.

7. Jensen P, Moller B, Hansen S: Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 2000, 42(2 Pt 1):1307.

8. Mortensen SA, Neumayer HH, Oyen O, Pascual J, Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M: Malignancy in renal transplantation. J Am Soc Nephrol 2004, 15(6):1582-1588.

9. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003, 63(3):917-926.

10. Yuan R, Kay A, Berg WJ, Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hemat Oncol 2009, 2:46.

11. Kasiske BL, Snyder JJ, Valantine H, Ahmed D, Albaranji J, Ames WA, Campistol JM, Eisen H, Frigerio M, Lehrkuhl H, Marcen R, Morris R, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007, 39(10):2937-2950.

12. Zmonarski SC, Boratynska M, Rabczynski J, Kazimierczak K, Klinger M: Interstitial pneumonitis associated with sirolimus. Transplant Proc 2005, 37(2):964-966.

13. Cullis B, D’Souza R, McCullagh P, Harries S, Nicholls A, Lee R, Bingham C: Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006, 47(5):67-72.

14. Zalmanson SC, Klinger M: Recurrence of Kaposi’s sarcoma after increased exposure to sirolimus. Int Immunopharmacol 2006, 6(13-14):2018-2022.

15. Zalmanson SC, Boratynska M, Rabczyńska J, Kazimierczak K, Klinger M: Regression of Kaposi’s sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 2005, 37(2):964-966.

16. Frigerio M, Lehmkuhl H, Marcen R, Morris R, Te_ref;e;_Morslo M, Muratori M, Silvestri F, Tosi G, Valsecchi M: Effect of sirolimus on post-transplantation lymphoproliferative disorder. Am J Kidney Dis 2006, 47(5):67-72.

17. Zalmanson SC, Klinger M: Recurrence of Kaposi’s sarcoma after increased exposure to sirolimus. Int Immunopharmacol 2006, 6(13-14):2018-2022.

18. Morath C, Schwenger V, Kroll-Rudek D, Sommerer C, Beimler J, Schmidt J, Zeier M: Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors. Transplant Proc 2007, 39(1):99-102.

19. Kasiske BL, Snyder JJ, Valantine H, Ahmed D, Albaranji J, Ames WA, Campistol JM, Eisen H, Frigerio M, Lehrkuhl H, Marcen R, Morris R, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007, 39(10):2937-2950.

20. Pham PT, Pham PC, Danovitch GW, Ross DJ, Gritsch HA, Kendrick EA, Singer J, Shah T, Wilkinson AH: Sirolimus-associated pulmonary toxicity. Transplantation 2004, 77B(12):1215-1220.

21. Kasiske BL, Snyder JJ, Valantine H, Ahmed D, Albaranji J, Ames WA, Campistol JM, Eisen H, Frigerio M, Lehrkuhl H, Marcen R, Morris R, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007, 39(10):2937-2950.

22. Kasiske BL, Snyder JJ, Valantine H, Ahmed D, Albaranji J, Ames WA, Campistol JM, Eisen H, Frigerio M, Lehrkuhl H, Marcen R, Morris R, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007, 39(10):2937-2950.
transplant: a rare complication of sirolimus. Nephrol Dial Transplant 2010, 25(8):2795-2798.

23. Flores-Franco RA, Luevano-Flores E, Gaston-Ramirez C: Sirolimus-associated desquamative interstitial pneumonia. Respirat 2007, 74(2):237-238.

24. Mingos MA, Kane GC: Sirolimus-induced interstitial pneumonitis in a renal transplant patient. Respir Care 2005, 50(12):1659-1661.

25. Chajed PN, Dickemann M, Bubendorf L, Mayr M, Steiger J, Tamm M: Patterns of pulmonary complications associated with sirolimus. Respirat 2006, 73(3):365-374.

26. Manito N, Kaplinsky LJ, Bernat R, Roca J, Castelli E, Serrano T, Esplugas E: Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. J Heart Lung Transplant 2004, 23(6):780-782.

27. Genebes C, Brouchet L, Kamar N, Lepage B, Prevot G, Rostaing L, Didier A, Mazieres J: Characteristics of thoracic malignancies that occur after solid-organ transplantation. J Thorac Oncol 2010, 5(1):1789-1795.

28. Boratynska M, Watorek E, Smolska D, Patrzalek D, Klinger M: Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 2007, 39(9):2736-2739.

29. Caillard S, Agodoa LY, Bohen EM, Abbott KC: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenic: involvement of vascular endothelial growth factor. Nat Med 2002, 8(2):128-135.

30. Ayral-Kaloustian S, Brouchet L, Kamar N, Le Page B, Prevot G, Rostaing L, Didier A, Mazieres J: Characteristics of thoracic malignancies that occur after solid-organ transplantation: characteristics, risk factors and prognosis. Transplantation 2006, 81(6):888-895.

31. Halkos ME, Miller JP, Mann KP, Miller DL, Gal AA: Thoracic presentations of posttransplant lymphoproliferative disorders. Chest 2004, 126(6):2013-2020.

32. Manito N, Kaplinsky LJ, Bernat R, Roca J, Castelli E, Serrano T, Esplugas E: Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. J Heart Lung Transplant 2004, 23(6):780-782.

33. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Homung M, Bruns CI, Zuerke C, Farkas S, Anthuber M, et al: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenic: involvement of vascular endothelial growth factor. Nat Med 2002, 8(2):128-135.

34. Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary L, Wang J, Li L, Young M, et al: Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. J Med Chem 2010, 53(1):452-459.

35. Kahan BD, Vapakoulou YK, Schoenberg L, Knight RJ, Katz SM, Lai D, Van Buren CT: Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005, 80(6):749-758.

36. Manito N, Kaplinsky LJ, Bernat R, Roca J, Castelli E, Serrano T, Esplugas E: Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. J Heart Lung Transplant 2004, 23(6):780-782.

37. Flieder DB, Travis WD: Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004, 25(3):583-592, vii.

38. Hashemi-Sadraei N, Sadpour S, Baram D, Miller F, Nord EP; Sirolimus-associated diffuse alveolar hemorrhage. Clin Chest Med 2004, 25(3):583-592, vii.

39. Flieder DB, Travis WD: Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004, 25(1):37-45.

40. Alasaly K, Muller N, Ostrans LN, Champion P, FitzGerald JM: Cryptogenic organizing pneumonia. A report of 25 cases and a review of the literature. Medicine (Baltimore) 1995, 74(4):201-211.

41. Flieder DB, Travis WD: Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004, 25(1):37-45.

42. Alasaly K, Muller N, Ostrans LN, Champion P, FitzGerald JM: Cryptogenic organizing pneumonia. A report of 25 cases and a review of the literature. Medicine (Baltimore) 1995, 74(4):201-211.